Markman Advisors
Patent Valuation, Monetization and Investments

Blog

Markman Advisors Patent Blog

Posts tagged Regeneron
Will Amgen win another injunction against Regeneron’s Praluent?

Amgen ($AMGN) is about to square off once again against Regeneron ($REGN) and Sanofi over whether Praluent® should be pulled from the market.  Having prevailed at another jury trial earlier this year showing that Amgen’s PCSK9 protein patents are both valid and infringed, Amgen has renewed its bid for a court order enjoining Praluent® from the market.  The injunction hearing is scheduled for June 2019.  Over two years ago, Amgen prevailed after an earlier injunction hearing where the court ordered Praluent® to be barred from the market.  Will Amgen be able to prevail again? 

Read More
For Amgen’s PCSK9 patent case, is there any read-through from Court’s summary judgment order to the trial?

On January 18, the District Court in Delaware issued an opinion resolving multiple summary judgment motions filed by both parties.  The key takeaway from that decision is that the case is now teed-up for trial beginning on February 19. But the Court didi highlight some key issues likely to be the focus of the trial.

Read More
What is Regeneron’s exposure from Novartis’ patent case against blockbuster Eylea®?

Novartis has filed a patent lawsuit against Regeneron seeking damages for sales of Eylea® and Zaltrap®.  On March 19, 2018, Novartis sued Regeneron in the Southern District of New York, White Plains Division, for infringing U.S. Patent No. 5,688,688.  The ‘688 patent claims gene expression constructs for the expression of polypeptides in mammalian cells.  How strong is Novartis’ case, and what is Regeneron’s exposure?

Read More
What is the status of Amgen’s PCSK9 patent lawsuit against Regeneron?

Regeneron ($REGN) and Sanofi released positive topline results from their ODYSSEY clinical trial Praluent®.  In addition was the announcement that prices for Praluent® may be cut.  Investors who may have grown skeptical with the new PCSK9-inhibitor class may now be interested again, which may include the pending patent lawsuit between Amgen ($AMGN) and Regeneron.  What is happening in the case?

Read More
What is the Dupixent® patent fight among Amgen, Regeneron and Sanofi all about?

Dupixent® is a recently-released drug forecasted to reach $4B in annual sales.  The drug is a co-venture between Regeneron and Sanofi, which also teamed up to launch Praluent®, one of the two available drugs within the new class of PCSK9-inhibitors.  In the case of Praluent®, Amgen brought Regeneron to court arguing that Praluent® infringed Amgen’s patents and thus the drug should be taken off the market.  Once again, Amgen, Regeneron and Sanofi are back in court.  Amgen has squared off against Regeneron and Sanofi and argued that Dupixent® infringes one of Amgen’s patents.

Read More